Cholangiocarcinoma

Web Exclusives — December 27, 2019

Barcelona, Spain—Ivosidenib (Tibsovo), an oral therapy that targets isocitrate dehydrogenase-1 (IDH1) mutation, significantly improved progression-free survival (PFS) in patients with advanced cholangiocarcinoma (CCA) and an IDH1 mutation, in a phase 3 clinical trial reported lead investigator Ghassan K. Abou-Alfa, MD, Medical Oncologist, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York City, at the ESMO Congress 2019.

Noninvasive Molecular Diagnosis Using Circulating DNA Sequencing Improves Outcomes in Cholangiocarcinoma Management

By Wayne Kuznar

Cholangiocarcinoma

Web Exclusives — October 14, 2019

Diagnosis of cholangiocarcinoma (CCA) is often identified at a late stage. Analyzing the tumor-specific mutation profile of a patient with CCA can improve the diagnosis and treatment for the individual patient. The molecular profile of CCA can be done through the use of circulating tumor (ct) DNA sequencing, which may help to target specific mutations and improve treatment selection for this rare type of cancer.

Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma

By Wayne Kuznar

Cholangiocarcinoma

Web Exclusives — August 7, 2018

Chicago, IL—A greater understanding of the biology of cholangiocarcinoma, including differences between intrahepatic versus extrahepatic cholangiocarcinoma, is driving the development of new therapeutic options that have shown promising results in advanced stages of this difficult-to-treat cancer.

Cholangiocarcinoma

Subscribe Today!

I'd like to receive:

Stay In The Know

Cholangiocarcinoma

Page 14 of 14

Subscribe Today!

I'd like to receive:

Stay In The Know